Fulcrum Therapeutics, INC 10-Q quarterly reports

Fulcrum Therapeutics details first-quarter 2026 financial results, highlighting progress in its lead drug candidate pociredir for Sickle Cell Disease and continued focus on rare disease therapies.

Fulcrum Therapeutics reported a net loss of $19.6 million for Q3 2025, driven by R&D focus on pociredir for sickle cell disease, which showed promising Phase 1b results, while the losmapimod program was terminated.

Fulcrum Therapeutics experienced significant net losses in Q2 2025 following the termination of its Sanofi collaboration and discontinuation of the Losmapimod program, while reporting promising Phase 1b clinical data for its lead sickle cell disease candidate, Pociredir.

Fulcrum Therapeutics reports a net loss of $17.7 million for Q1 2025, focusing on pociredir development and inherited aplastic anemia programs.

Fulcrum Therapeutics reported a net income of $6.8 million for the nine months ended September 30, 2024, primarily due to a collaboration agreement, and announced a strategic shift in research and development focus.

Fulcrum Therapeutics has entered into a significant collaboration and license agreement with Sanofi, granting exclusive rights to commercialize losmapimod, a potential treatment for facioscapulohumeral muscular dystrophy (FSHD), outside the United States.

Fulcrum Therapeutics reported a net loss of $26.9 million for the first quarter of 2024, while also announcing a significant collaboration with Sanofi for ex-US commercialization of losmapimod.